Fulgent Pharmacogenetic Testing (PGx)

Overview

Pharmacogenetic (PGx) testing tells us how genetic factors impact a person's ability to process and respond to medications. With this information, you can tailor medication plans to an individual's genetic makeup. This can increase the effectiveness of medications while reducing the risk of adverse drug reactions (ADR).

Fulgent's PGx testing is available to clinicians, researchers, and interested individuals with a written physcian's order.

What Testing Can Tell Us

PGx testing can reveal if a person is a fast, normal, or slow metabolizer. A person's metabolism changes the way their body responds to medication, including:

Toxicity

Excessive amounts of the drug accumulate in the bloodstream, resulting in ADRs.

Hypersensitivity

Normal amounts of the drug enter the bloodstream, but even this is enough to trigger severe reactions in people with hypersensitivity to the medication.

Lack of Efficacy

The bloodstream cannot absorb enough of the drug to achieve a therapeutic effect.

Our Products

Focus Panel

Gene Count:

18

Includes clincally actionable gene/drug associations that have evidence-based guideline for therapeutic management.

Learn More

Comprehensive Panel

Gene Count:

44

Includes all the gene/drug associations in the focused panel as well as associations with a PharmGKB evidence level of 2 or higher. Evidence for these associations are significant, but not as high as those in the focused panel.

Learn More

Download our PGx flyer to learn more.

Download Flyer

Why Use PGx Testing?

Research shows that over 90 percent of people carry at least one PGx response variant and 65 percent of people are exposed to at least one PGx relevant drug. With PGx testing, you can learn about potential adverse reactions before an individual ever takes a drug, reducing the risk of "trial-and-error" prescribing.

Benefits of Testing

Minimize Costs

Patients can have varying responses to medication depending on their metabolism and genetic markers. PGx testing can help clinicians choose the most effective drug for each patient, saving them both time and money.

Reduce Risk of ADR

The FDA estimates that 6.7% of hospitalized paitents have ADR every year, many of which could be prevented. PGx testing can assess the risk of an ADR before a patient ever takes the medication, leading to increased patient safety and reduced costs for healthcare facilities.

ADR Facts

Optimize Medication Plans

Creating a regimen designed for a patient's specific genetic markers and metabolism is important when prescribing medication. PGx testing can help clinicans select a dosage that efficiently treats the patient's symptoms.